Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and children

British Journal of Pharmacology

Volumn 153, Issue 6, 2008, Pages 1120-1127

  Nowak Gottl U ^a,d   Bidlingmaier, C ^b   Krumpel A ^a   Gottl L ^a   Kenet, G ^c  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c SHEBA MEDICAL CENTER   (Israel)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Children; Dalteparin; Enoxaparin; Reviparin and tinzaparin; Safety and efficacy

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; REVIPARIN; TINZAPARIN; WARFARIN;

BLEEDING; CEREBROVASCULAR ACCIDENT; CHILD; CHILD CARE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HAIR LOSS; HUMAN; INFANT; INJECTION PAIN; LUNG EMBOLISM; NEWBORN; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOEMBOLISM; TIME TO MAXIMUM PLASMA CONCENTRATION; VEIN THROMBOSIS;

CHILD; CHILD, PRESCHOOL; CONTROLLED CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG LABELING; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFANT; INFANT, NEWBORN; STROKE; THROMBOEMBOLISM; THROMBOSIS;

EID: 40949087700     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707447     Document Type: Review

References (58)

1. Albisetti M, Andrew M (2002). Low molecular weight heparin in children. Eur J Pediatr 161: 71.
2. Al-Yaseen E, Wells PS, Anderson J, Martin J, Kovacs MJ (2005). The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J Thromb Haemost 3: 100-102.
3. Andrew M (1995). Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost 74: 415-425.
4. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L (1992). Maturation of the hemostatic system during childhood. Blood 80: 1998-2005.
5. Bidlingmaier C, Magnani HN, Girisch M, Kurnik K (2006). Safety and efficacy of danaparoid (orgaran) use in children. Acta Haematol 115: 237-247.
6. Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS (2000). Gestational outcome in thrombophilic women treated for recurrent pregnancy loss. Thromb Haemost 83: 693-697.
7. Broyer M, Gagnadoux MF, Sierro A, Fischer AM, Revillon Y, Jan D et al. (1991). Prevention of vascular thromboses after renal transplantation using low molecular weight heparin. Ann Pediatr (Paris) 38: 397-399.
8. Burak CR, Bowenn MD, Barron TF (2003). The use of enoxaparin in children with acute, no hemorrhagic ischemic stroke. Pediatr Neurol 29: 295-298.
9. Chalmers EA (2005). Perinatal stroke - risk factors and management. Br J Haematol 130: 333-343.
10. Collignon F, Frydman A, Caplain H, Ozoux ML, Roux YL, Bouthier J et al. (1995). Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (dose for prevention of thromboembolism). Thromb Haemost 73: 630-640.
11. Couturaud F, Julian JA, Kearon C (2001). Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism. Meta-analysis. Thromb Haemost 86: 980-984.
12. DeVeber G, Andrew M, Adams C, Bjornson B, Booth F, Buckley DJ et al. (2001). Cerebral sinovenous thrombosis in children. N Engl J Med 345: 417-423.
13. Dix D, Andrew M, Marzinotto V, Charpentier K, Bridge S, Monagle P et al. (2000). The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 136: 439-445.
14. Elhasid R, Lanir N, Sharon R, Arush BMW, Levin C, Postovsky S et al. (2001). Prophylactic therapy with enoxaparin during L- asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 12: 367-370.
15. Greaves M (2002). Limitations of the laboratory monitoring of heparin therapy. scientific and standardization committee communications: on behalf of the control of anticoagulation subcommittee of the scientific and standardization committee of the international society of thrombosis and haemostasis. Thromb Haemost 87: 163-164.
16. Greer I, Hunt BJ (2004). Low molecular weight heparin in pregnancy: current issues. Br J Haematol 128: 593-601.
17. Haas CE, Nelsen JL, Raghavendran K, Mihalko W, Beres J, Ma Q et al. (2005). Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. J Trauma 59: 1336-1344.
18. Hainer JW, Sprogel P, Lindenstroem E (2004). Extending the role of antithrombotic agents: an example based on the low-molecular-weight heparin, tinzaparin. Semin Thromb Hemost 30: 3-9.
19. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J et al. (1998). Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 114: S445-S469.
20. Hirsh J, Levine M (1992). Low molecular weight heparin. Blood 79: 1-17.
21. Hirsh J, Raschke R (2004). Heparin and low-molecular-weight heparin. the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126: 188-203.
22. Ho SH, Wu JK, Hamilton DP, Dix DB, Wadsworth LD (2004). An assessment of published pediatric dosage guidelines for enoxaparin. J Pediatr Hematol Oncol 26: 561-566.
23. Hofmann S, Knoefler R, Lorenz N, Siegert G, Wendisch J, Mueller D et al. (2001). Clinical experience with low-molecular weight heparins in pediatric patients. Thromb Res 103: 345-353.
24. Jackson CM, White GC, Barrowcliffe T, Esnouf MP, Jespersen J, Kluft C et al. (2002). A reference system approach to future standardization of laboratory tests for hemostasis. Thromb Haemost 87: 165-169.
25. Kay R, Wong KS, Yu YL, Chan YW, Tsoi TH, Ahujy AT et al. (1995). Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 333: 1588-1593.
26. Kosch A, Kuwertz-Bröking E, Heller C, Kurnik K, Schobess R, Nowak-Göttl U (2004). Renal venous thrombosis in neonates: prothrombotic risk factors and long-term follow-up. Blood 104: 1356-1360.
27. Kreuz W, Stoll M, Junker R, Heinecke A, Schobess R, Kurnik K et al. (2006). Familial elevated factor VIII in children with symptomatic venous thrombosis and postthrombotic syndrome. Results of a multicentre study. Arterioscler Thromb Vasc Biol 26: 1901-1906.
28. Kuhle S, Massicotte P, Dinyari M, Vegh P, Mitchell D, Marzinotto V et al. (2005). Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost 94: 1164-1171.
29. Laporte S, Mismetti P, Piquet P, Doubine S, Touchot A, Decousus H (1999). Population pharmacokinetic of nadroparin calcium (Fraxiparine) in children hospitalised for open heart surgery. Eur J Pharm Sci 8: 119-125.
30. Lee AY, Levin MN, Baker RI, Bowden C, Kakkar AK, Prins M et al. (2003). Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. N Engl J Med 349: 146-153.
31. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S (2004). Hemorrhagic complications of anticoagulant treatment. Chest 126: S287-S310.
32. Lim W, Dentali F, Eikelboom W, Crowther MA (2006). Meta-analysis: low-molecular-weight heparin and bleeding in patients with sever renal insufficiency. Ann Intern Med 144: 673-684.
33. López-Jiménez L, Montero M, González-Fajardo JA, Arcelus JI, Suárez C, Lobo JL et al. (2006). Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica 91: 1046-1051.
34. Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M (1996). Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 128: 313-318.
35. Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B et al. (2003a). An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 109: 85-92.
36. Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B et al. (2003c). An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: The PROTEKT trial. Thromb Res 109: 101-108.
37. Massicotte P, Julian JA, Marzinotto V, Gent M, Shields K, Chan AK et al. (2003b). Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thromb Res 109: 93-99.
38. Merkel N, Günther G, Schobess R (2006). Long-term treatment of thrombosis with enoxaparin in pediatric and adolescent patients. Acta Haematol 115: 230-236.
39. Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A et al. (2001). Subcutaneous Enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 134: 191-202.
40. Michaels LA, Gurian M, Hegyi T, Drachtman RA (2004). Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant. Pediatrics 114: 703-707.
41. Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD (2004). Antithrombotic therapy in children. Chest 126: S645-S687.
42. Newall F, Barnes C, Ignjatovic V, Monagle P (2003). Heparin-induced thrombocytopenia in children. J Paediatr Child Health 39: 289-292.
43. Nohe N, Flemmer A, Rümler R, Praun M, Auberger K (1999). The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr 158: S134-S139.
44. Norris LA, Bonnar J, Smith MP, Steer PJ, Savidge G (2004). Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. Thromb Haemost 92: 791-796.
45. Nowak-Göttl U, Günther G, Kurnik K, Sträter R, Kirkham F (2003). Arterial ischemic stroke in neonates, infants, and children: an overview of underlying conditions, imaging methods, and treatment modalities. Semin Thromb Hemost 29: 405-414.
46. Nowak-Göttl U, Junker R, Kreuz W, von Eckardstein A, Kosch A, Nohe N et al. (2001a). Risk factors for recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 97: 858-862.
47. Nowak-Göttl U, Kosch A, Schlegel N (2001b). Thromboembolism in newborns, infants and children. Thromb Haemost 86: 464-474.
48. Punzalan RC, Hillery CA, Montgomery RR, Scott CA, Gill JC (2000). Low-molecular-weight heparin in thrombotic disease in children and adolescents. J Pediatr Hematol Oncol 22: 137-142.
49. Ranze O, Ranze P, Magnani HN, Greinacher A (1999). Heparin-induced thrombocytopenia in paediatric patients-a review of the literature and a new case treated with danaparoid sodium. Eur J Pediatr 158: 130-133.
50. Revel-Vilk S, Sharathkumar A, Massicotte P, Marzinotto V, Daneman A, Dix D et al. (2004). Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: a longitudinal study by ultrasound. J Thromb Haemost 2: 42-46.
51. Samama NM, Gerotziafas GT (2000). Comparative pharmacokinetics of LMWHs. Sem Thromb Hemost 26: 31-38.
52. Sanderink GJ, Le Liboux A, Jariwala N, Harding N, Ozoux ML, Shukla U et al. (2002). The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 73: 308-318.
53. Schobess R, Düring C, Bidlingmaier C, Heinecke A, Merkel N, Nowak-Göttl U (2006). Long-term safety and efficacy date on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration. Haematologica 91: 1704-1707.
54. Shama A, Patole SK, Whitehall JS (2002). Low molecular weight heparin for neonatal thrombosis. J Paediatr Child Health 38: 615-617.
55. Shojania AM (2004). More on: is laboratory monitoring of low-molecular-weight heparin necessary? J Thromb Haemost 2: 2276-2277.
56. Sträter R, Kurnik K, Heller C, Schobess R, Luigs P, Nowak-Göttl U (2001). Aspirin versus low-dose low molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients. Stroke 32: 2554-2558.
57. Streif W, Goebel G, Chan AK, Massicotte P (2003). Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients. Arch Dis Child Fetal Neonatal Ed 88: F365-F370.
58. Wilson SJ, Wilbur K, Burton E, Anderson DR (2001). Effect of patient weight on the anticoagulant response to adjust therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis 31: 42-48.